Tvardi Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
Revenue | $0 | $2,569 | $1,455 | $2,556 |
Gross Profit | -47 | 2,569 | 1,413 | 2,483 |
EBITDA | -8,822 | -2,039 | -5,456 | -10,443 |
EBIT | -8,869 | -2,386 | -6,001 | -10,516 |
Net Income | 4,167 | -4,906 | -7,679 | -12,476 |
Net Change In Cash | 0 | 2,569 | 1,455 | 2,556 |
Free Cash Flow | -8,865 | -4,692 | -4,043 | -13,984 |
Cash | 20,648 | 34,217 | 37,903 | 9,438 |
Basic Shares | 8,455 | 9,355 | 1,523 | 1,523 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $7,137 | $20,968 | $41,867 | $23,028 |
Gross Profit | 6,325 | 14,535 | 34,353 | 21,474 |
EBITDA | -62,600 | -17,252 | -20,454 | -86,887 |
EBIT | -62,792 | -17,347 | -20,539 | -88,441 |
Net Income | -70,867 | -17,347 | -20,542 | -88,441 |
Net Change In Cash | 7,137 | 20,968 | 41,867 | 23,028 |
Free Cash Flow | -61,963 | -21,040 | -17,916 | -60,126 |
Cash | 37,903 | 22,919 | 21,489 | 13,453 |
Basic Shares | 1,520 | 9,355 | 9,355 | 1,408 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | $0.51 |
2025-03-31 | -$0.50 |
2024-12-31 | -$5.03 |
2024-09-30 | -$8.18 |
